AstraZeneca and Rossari Biotech posted their highest revenue in 13 quarters, with Rossari also seeing increased institutional interest.
Two mid-cap stocks are showing fresh technical setups with strong quarterly metrics.
Astrazeneca Pharmaceuticals
According to SEBI-registered research analyst Gunjan Kumar, AstraZeneca Pharma is forming an ascending triangle pattern breakout on the charts.
He advised watching the stock above ₹9,350, with ₹9,000 as support on a closing basis.
On the fundamentals front, he pointed out that the company is almost debt-free and has reported the highest revenue and profit in the last 13 quarters.
The company’s return on capital employed (ROCE) is above 33, and return on equity (ROE) is above 23.
Rossari Biotech
Kumar also highlighted Rossari Biotech, stating that both foreign institutional investors (FIIs) and domestic institutional investors (DIIs) increased their stakes in the previous quarter.
He said the stock is undervalued and has posted its highest revenue in the last 13 quarters.
On the technical side, he observed a trendline breakout and recommended watching the stock above ₹715, with a closing support at ₹669.
On Stocktwits, both AstraZeneca and Rossari Biotech saw ‘normal’ message volume; sentiment was ‘neutral’ for AstraZeneca and ‘bullish’ for Rossari.
AstraZeneca’s stock has risen 26.7% so far in 2025, while Rossai’s stock has declined 11.9% during the same period.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<